<unk>  as monotherapy is indicated for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA).
Moxetumomab pasudotox
Loncastuximab tesirine
Ibritumomab tiuxetan
Sacituzumab govitecan
CimaVax-EGF
Trastuzumab deruxtecan
Tositumomab
Nivolumab/relatlimab